Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xeris Pharmaceuticals (XERS – Research Report), AMN Healthcare Services (AMN – Research Report) and 4D Molecular Therapeutics (FDMT – Research Report).
Xeris Pharmaceuticals (XERS)
Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Xeris Pharmaceuticals on May 9 and set a price target of $5.00. The company’s shares closed last Monday at $1.89.
According to TipRanks.com, Ruiz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $4.75 average price target, a 162.4% upside from current levels. In a report issued on May 6, Craig-Hallum also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
AMN Healthcare Services (AMN)
In a report issued on May 9, Mark Marcon from Robert W. Baird maintained a Hold rating on AMN Healthcare Services, with a price target of $60.00. The company’s shares closed last Monday at $59.01, close to its 52-week low of $53.00.
According to TipRanks.com, Marcon is a 5-star analyst with an average return of
AMN Healthcare Services has an analyst consensus of Moderate Buy, with a price target consensus of $69.00, a 24.4% upside from current levels. In a report issued on May 2, Benchmark Co. also maintained a Hold rating on the stock.
4D Molecular Therapeutics (FDMT)
In a report issued on May 9, Mani Foroohar from Leerink Partners reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $35.00. The company’s shares closed last Monday at $25.57.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 4D Molecular Therapeutics with a $46.17 average price target, which is a 78.0% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $40.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XERS:
- Xeris Biopharma price target lowered to $3 from $4 at Piper Sandler
- Xeris Biopharma reports Q1 EPS (14c), consensus (12c)
- Xeris Biopharma enters collaboration, license agreement with Beta Bionics
- Xeris Biopharma enters exclusive license agreement with Beta Bionics
- Xeris Biopharma initiated with an Outperform at Oppenheimer
